Alain Tonnerre
University of Nantes
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alain Tonnerre.
ACS Medicinal Chemistry Letters | 2013
Rémi Guillon; Fabrice Pagniez; Carine Picot; Damien Hédou; Alain Tonnerre; Elizabeth Chosson; Muriel Duflos; Thierry Besson; Cédric Logé; Patrice Le Pape
Synthesis of a strict structural analogue of albaconazole in which the quinazolinone ring is fused by a thiazole moiety led to the discovery of a new triazole with broad-spectrum antifungal activity. Compound I exhibited high in vitro activity against pathogenic Candida species and filamentous fungi and showed preliminary in vivo antifungal efficacy in a mice model of systemic candidiasis.
Journal of Enzyme Inhibition and Medicinal Chemistry | 2003
Emmanuelle Braud; Muriel Duflos; Marie-Renee Nourrisson; Alain Tonnerre; Carine Picot; Guillaume Le Baut; Pierre Renard; Bruno Pfeiffer; Gordon Tucker
The synthesis and pharmacological evaluation of new 3-(imidazol-4(5)-ylmethylene)indolin-2-ones, analogues of SU-5416, are reported. The final compounds 20-51 were obtained by Knoevenagel coupling between the substituted indolin-2-ones 1-15 and either the formylimidazole derivatives 16-18 or 2-formyl-3,5-dimethylpyrrole 19. Methylation at the nitrogen atom of the indolin-2-one and/or imidazole moities was carried out in the presence of the couple NaH/DMF. A Mannich reaction afforded the 1-dimethylaminomethyl derivatives 43 and 48. The antiangiogenic activity of these compounds was evaluated in a three dimensional in vitro rat aortic ring assay. In this test, compound 20 induced a decrease of angiogenesis comparable to that observed with SU-5416; the vascular density indexes at 1 μM were 30±18 and 22±4 % of control, respectively. The compounds were also evaluated, in an independent manner, as inhibitors of the human EGF-receptor tyrosine kinase activity. As expected, only minor activities were observed with four compounds, out of thirty-one, exerting inhibitory effects in the range of 40-55 % at 10 μM concentration.
European Journal of Medicinal Chemistry | 2016
David Montoir; Sophie Barillé-Nion; Alain Tonnerre; Philippe Juin; Muriel Duflos; Marc-Antoine Bazin
Hsp90 is an ATP-dependent chaperone known to be overexpressed in many cancers. This way, Hsp90 is an important target for drug discovery. Novobiocin, an aminocoumarin antibiotic, was reported to inhibit Hsp90 targeting C-terminal domain, and showed anti-proliferative properties, leading to the development of new and more active compounds. Consequently, a new set of novobiocin analogs derived from 1,6-naphthyridin-2(1H)-one scaffold was designed, synthesized and evaluated against two breast cancer cell lines. Subsequently, cell cycle progression and apoptosis were conducted on best candidates, finally Western Blot analysis was performed to measure their ability to induce degradation of Hsp90 client proteins.
Tetrahedron Letters | 2013
Marc-Antoine Bazin; Sophie Marhadour; Alain Tonnerre; Pascal Marchand
European Journal of Organic Chemistry | 2014
David Montoir; Alain Tonnerre; Muriel Duflos; Marc-Antoine Bazin
Tetrahedron | 2015
David Montoir; Alain Tonnerre; Muriel Duflos; Marc-Antoine Bazin
Archive | 1998
Timothee Muller; Claudie Moulin; Muriel Duflos; Sylvie Robert-Piessard; Guillaumu Le Baut; Alain Tonnerre; Caignard Daniel Henri; Manechez Dominique; Renard Pierre
Tetrahedron Letters | 2018
Ousmane Dembélé; David Montoir; Thomas Yvorra; Dylan Sérillon; Alain Tonnerre; Muriel Duflos; Jean-Michel Robert; Marc-Antoine Bazin
Archive | 1997
Daniel-Henri Caignard; Dominique Manechez; Pierre Renard; Timothee Muller; Claudie Moulin; Muriel Duflos; Sylvie Robert-Piessard; Alain Tonnerre; Baut Guillaume Le
Archive | 1997
Timothee Muller; Claudie Moulin; Muriel Duflos; Sylvie Robert-Piessard; Baut Guillaume Le; Alain Tonnerre